Trials / Not Yet Recruiting
Not Yet RecruitingNCT06439550
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- The First Affiliated Hospital of Zhengzhou University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab，Trastuzumab and SOX in the adjuvant treatment of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Serplulimab | 300mg, q3w |
| DRUG | Trastuzumab | First dose 8mg/kg, maintenance 6mg/kg, q3w |
| DRUG | Oxaliplatin + Tegafur | oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w). |
Timeline
- Start date
- 2024-07-15
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2024-06-03
- Last updated
- 2024-06-03
Source: ClinicalTrials.gov record NCT06439550. Inclusion in this directory is not an endorsement.